Use of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone is promising for patients with bortezomib-refractory MM, results PANORAMA 2, a single arm, Phase 2 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition have found.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.